Eocene Ltd. (EOCN)
NASDAQ: EOCN · Real-Time Price · USD
3.070
+0.220 (7.72%)
At close: Oct 20, 2026, 4:00 PM EDT
3.070
0.00 (0.00%)
After-hours: Oct 20, 2026, 4:00 PM EDT
Eocene Employees
As of December 31, 2025, Eocene had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees did not change compared to the previous year. That makes Eocene the 41,336th largest employer in the world and 6,369th in the United States.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,890,500
Market Cap
3.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - | 3 | 3 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 3 | 3 |
| Dec 31, 2023 | 8 | -2 | -20.00% | 3 | 5 |
| Dec 31, 2022 | 10 | -14 | -58.33% | 4 | 6 |
| Dec 31, 2021 | 24 | 0 | - | 19 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| Calidi Biotherapeutics | 29 |
| VivoSim Labs | 15 |
| Dermata Therapeutics | 9 |
| Ernexa Therapeutics | 7 |
| Mustang Bio | 4 |
| GRI Bio | 4 |
EOCN News
- 5 weeks ago - Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation - PRNewsWire
- 2 months ago - Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PRNewsWire
- 2 months ago - Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - PRNewsWire
- 2 months ago - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PRNewsWire
- 3 months ago - Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PRNewsWire
- 4 months ago - Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd. - PRNewsWire
- 4 months ago - Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - PRNewsWire
- 4 months ago - Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PRNewsWire